Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
Holding MRK?
Track your performance easily
MRK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$94.48 - $134.63
Previous Close$99.52
Volume29.29M
Average Volume (3M)11.05M
Market Cap
$251.75B
Enterprise Value$275.35B
Total Cash (Recent Filing)$14.59B
Total Debt (Recent Filing)$38.13B
Price to Earnings (P/E)20.8
Beta0.21
Next Earnings
Feb 04, 2025EPS Estimate
$1.81Last Dividend Ex-Date
Dec 16, 2024Dividend Yield3.13%
Share Statistics
EPS (TTM)4.77
Shares Outstanding2,529,635,645
10 Day Avg. Volume13,262,821
30 Day Avg. Volume11,049,261
Standard Deviation0.06
R-Squared0.11
Alpha0.00223
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)5.66
Price to Sales (P/S)3.94
Price to Cash Flow (P/CF)6.70
P/FCF Ratio7.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.36
Enterprise Value/Gross Profit6.26
Enterprise Value/Ebitda14.56
Forecast
1Y Price Target
$127.43Price Target Upside29.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Product DevelopmentMRK has entered into a global license agreement with Hansoh Pharma for HS-10535, a preclinical oral small molecule GLP-1 receptor agonist for diabesity, which could provide a potential asset that could enter the future $150bn diabesity market.
Regulatory StrategyMerck plans to submit ZENITH results to FDA for additional labeling considerations, which could help further accelerate an already impressive launch, providing incremental revenue and share upside.
Sales And Market ExpansionMerck management is confident they can exceed the $11B annual sales target for Gardasil in 2030, demonstrating strong growth potential and market confidence.
Bears Say
Gardasil Revenue ConcernsGardasil remains a concern with revenues -10% vs. consensus, likely continued to be impacted by problems in China.
Inventory ChallengesManagement expects 4Q shipments to remain at a similar level as 3Q, indicating ongoing inventory challenges.
Pipeline DiscontinuationMRK announced it is discontinuing pipeline programs for vibostolimab and favezelimab, which are next-gen immuno-oncology assets the company was exploring in combination with Keytruda.
---
Ownership Overview
0.04% Insiders
21.50% Mutual Funds
15.62% Other Institutional Investors
42.49% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $94.48 and its highest was $134.63 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 04, 2025 which is in 43 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 31, 2024. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $1.484 by $0.086.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.81 which represents an annual dividend yield of 3.13%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is $1.81.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,529,635,700 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $1.57 in its last earnings report, beating expectations of $1.484. Following the earnings report the stock price went down -2.394%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 2B.
---
Merck & Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$127.43 (29.96% Upside)
$127.43 (29.96% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 32.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.99%
12-Months-Change
Fundamentals
Return on Equity
28.33%
Trailing 12-Months
Asset Growth
10.12%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
MRK Company Deck
---
MRK Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several strong performance areas, such as revenue growth driven by KEYTRUDA and animal health, and a robust pipeline expansion. However, challenges in China and the decline in GARDASIL sales, particularly in China, were notable lowlights. Overall, the sentiment leans towards positive due to strong growth drivers and future potential.Read More>---
MRK Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
MRK Stock 12 Month Forecast
Average Price Target
$127.43
▲(29.96% Upside)
Technical Analysis
Best Analysts Covering MRK
1 Year
1 Year Success Rate
39/53 ratings generated profit
1 Year Average Return
+12.80%
reiterated a buy rating 11 months ago
Copying Mara Goldstein's trades and holding each position for 1 Year would result in 73.58% of your transactions generating a profit, with an average return of +12.80% per trade.
---